doi: 10.1186/s12933-018-0763-3
Editors Picks This week Novo Nordisk announced the launch of their weight-loss (GLP1) pill in the US
Triple Agonists (GLP-1/GIP/Glucagon) Class Overview Monograph At a glance Prototype agent / retatrutide (LY3437943), Eli Lilly Mechanism / simultaneous GLP-1R, GIPR, and glucagon receptor co-agonism Phase 2 peak weight loss / up to 24.2% body weight at 48 weeks (retatrutide 12 mg) Primary indications in development / obesity, type 2 diabetes, MASLD/MASH, dyslipidemia Route and frequency / once-weekly subcutaneous injection Key differentiator from dual agonists / added glucagon receptor activity drives hepatic fat mobilization and energy expenditure Most common adverse effects / nausea, vomiting, diarrhea, constipation (dose-dependent) Regulatory status (as of mid-2025) / phase 3 trials ongoing
Improve how your body handles insulin / blood sugar (very helpful in type 2 diabetes)
doi: 10.1016/j.abb.2015.11.032
Planned Parenthood offers many discounted and free services, including pregnancy tests, birth control, and services related to sexual health The Substance Abuse and Mental Health Services Administration (SAMHSA) offers a confidential, free service for anyone needing assistance with substance and mental health concerns
